News > Latest News

Walk News | Sponsor & Foundation News | News in the Parkinson's Disease Community

Lundbeck to acquire Prexton Therapeutics

(March 20, 2018) - Lundbeck announced that they will acquire Prexton Therapeutics. By acquiring Prexton, Lundbeck will obtain global rights of an attractive compound (foliglurax) which currently is in clinical phase II testing for symptomatic treatment of OFF-time reduction in Parkinson’s disease and dyskinesia including Levodopa Induced Dyskinesia (LID). First data from the ongoing clinical phase II trial is expected to be available during the first half of 2019. Read more